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 Chapter 11 
 Gene Delivery and Expression Systems 
in Induced Pluripotent Stem Cells 
 Maolin  Zhang ,  Kunimichi  Niibe ,  Takeru  Kondo ,  Yuya  Kamano , 
 Makio  Saeki , and  Hiroshi  Egusa 
 Abstract  Induced pluripotent stem (iPS) cells, which can be generated from 
somatic cells by genetic manipulation, are invaluable experimental and therapeutic 
tools for development of tissue regeneration technologies. Many studies have dem-
onstrated that gene delivery to pluripotent stem cells is useful for basic studies in 
developmental biology and for driving differentiation toward a specifi c cell lineage 
for regenerative applications. Several gene delivery systems using viral and nonviral 
vectors have been used for stem cell research. These gene delivery systems are 
designed to accommodate specifi c research purposes; thus, each of them possesses 
its own advantages and disadvantages according to the experimental design. In 
addition, the type of constitutive promoter in the expression vector greatly affects 
the transcriptional activity of transgenes in pluripotent stem cells. Therefore, it is 
necessary to consider the characteristics of the vectors and their promoters when 
selecting a gene delivery system to transfer the target gene into iPS cells. In this 
mini-review, characteristics of commonly used viral (adenoviral, adeno-associated 
viral, retroviral, and lentiviral) vectors and a nonviral  piggyBac transposon DNA 
vector with constitutive promoters are outlined to support the selection of an appro-
priate gene delivery and expression system for iPS cell research. 
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11.1  Introduction 
 Stem cells, which are characterized as immature, self-renewal, and undifferentiated 
cells that can give rise to many different cell lineages, are expected to open new 
needed therapeutic avenues [ 1 ]. Induced pluripotent stem (iPS) cells are cells repro-
grammed from somatic cells via genetic modifi cation to obtain embryonic stem 
(ES) cell characteristics [ 2 ,  3 ]. Although multipotent adult stem cells such as mes-
enchymal stem cells (MSCs) have been well investigated for clinical application 
[ 4 ], basic research on pluripotent stem cells, such as ES cells and iPS cells, may lead 
to further understanding of in vitro tissue/organ development, which in turn could 
be applied to next-generation therapeutic approaches for whole-tissue/organ 
regeneration. 
 Gene delivery to pluripotent stem cells provides a powerful experimental system 
to investigate the early stages of tissue/organ development. In addition, genetic 
modifi cation of patient-specifi c iPS cells, particularly disease-model iPS cells, 
could facilitate the study of pathological mechanisms and provide new therapeutic 
approaches in personalized medicine [ 5 ]. To obtain effi cient and stable transgene 
expression, various gene delivery methods ranging from viral vectors to plasmid- 
based transient gene expression have been applied to pluripotent stem cells [ 6 ]. In 
these methods, many types of constitutive promoters have been utilized in the 
expression vectors, such as the cytomegalovirus (CMV), human elongation factor 
1α (EF1α), CMV enhancer/ β -actin promoter with  β -actin intron (CA), Rous sar-
coma virus (RSV) [ 7 ], human β-actin (ACTB), phosphoglycerate kinase (PGK) [ 8 ], 
and simian virus 40 early (SV40) [ 9 ] promoters. The transcriptional activity of 
transgenes considerably varies among these promoters depending on the cell type 
[ 10 ]. Notably, the CMV promoter, which is one of the most popular choices for gene 
delivery vectors because of its strong activity in most cell lines, shows considerably 
weak transgene activation in stem cells [ 7 ,  8 ,  11 – 14 ]; therefore, it is important to 
select an optimal promoter to obtain the expected transgene expression in iPS cell 
experiments. 
 Beyond the constitutive promoter systems described above, regulated control of 
gene expression has great signifi cance for stem cell research because of the ability 
to avoid undesirable effects of constitutive transgene expression after cellular dif-
ferentiation [ 15 ]. Several studies have employed tetracycline (tet)-regulated sys-
tems to control transgene expression in both ES cells and iPS cells, thereby enabling 
the transgene function to be explored in a spatiotemporal manner [ 16 – 18 ]. Each 
gene delivery and expression system has particular advantages and disadvantages 
depending on the desired outcome of the experimental design. Here, we briefl y 
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review representative gene delivery and expression systems from the perspective of 
their application to iPS cell research. 
11.2  Viral-Based Gene Delivery Systems 
 Gene delivery systems are classifi ed into two major classes: virus-based vectors and 
nonviral vectors (Table  11.1 ). Viruses are suitable for effi cient gene delivery experi-
ments because of their ability to penetrate into the cell nucleus and replicate [ 19 ]. 
Viral vectors have been widely used to deliver foreign genes into the cell nucleus 
because of their high transduction effi ciency and capacity for long-term transgene 
expression [ 20 ]. Ideally, the vector should be nontoxic, minimally immunogenic, 
and capable of highly effi cient penetration and delivery to numerous cell types [ 21 ]. 
The principal viral vectors currently in use include adenovirus, adeno-associated 
virus (AAV), retrovirus, and lentivirus [ 22 ].
11.2.1  Adenovirus Vectors 
 Adenovirus, a 70–100-nm, non-enveloped, double-stranded DNA virus [ 23 ], 
belongs to the family  Adenoviridae and is well known to cause respiratory tract 
infections. Adenoviruses enter mammalian cells via attachment to the  Coxsackievirus 
and adenovirus receptor (CAR) [ 24 ]. Adenoviruses rarely integrate with the host 
genome because their genome is maintained episomally in the cell nucleus. Because 
of their ability to transduce many cell types, including both dividing and nondivid-
ing cells, without genomic integration, adenoviral vectors have been considered as 
 Table 11.1  Comparison of commonly used viral vectors and  piggyBac transposon system 













 DNA  DNA  RNA  RNA  DNA 
 Packaging 
capacity [ 32 ] 
 4–5 kb  5 kb  9–12 kb  8 kb  9–14 kb 
 Genome 
integration 
 No  No  Yes  Yes  Yes 
(removable: 
cut and paste) 
 Gene 
expression 
 Transient  Transient/stable  Stable  Transient/stable  Stable 
 Applicable 
cell types 
 Broad  Broad  Dividing 
cells only 
 Broad  Broad 
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promising delivery systems for gene transduction experiments. However, the tran-
sient nature of their transgene expression limits their utility in in vitro research 
designs, and the toxicity and associated immune responses may hamper their clini-
cal application. 
 Adenovirus vectors can easily introduce exogenous genes into mouse ES cells 
[ 7 ] and iPS cells [ 13 ], and they are also used as effective gene delivery tools for 
human ES cells and iPS cells [ 25 ]. The transient expression mediated by adenovirus 
vectors is actually an advantage for stem cell research, in that undesirable effects of 
constitutive transgene expression after cell differentiation can be avoided. Indeed, 
adenovirally mediated transient expression of  Runx2 or  PPARγ was shown to effi -
ciently guide mouse iPS cells to differentiate into osteoblasts or adipocytes, respec-
tively [ 13 ]. 
 It should be noted that selection of an appropriate constitutive promoter, such as 
EF1α and CA promoters, is important for effective adenoviral transgene expression 
in pluripotent stem cells [ 26 ]. When used in adenovirus vectors, the CMV and RSV 
promoters show weak activity in mouse pluripotent stem cells [ 7 ,  13 ] because they 
are silenced by DNA methylation [ 27 ,  28 ]; therefore these promoters may not be the 
best choice for adenoviral transduction experiments in iPS cell research. 
11.2.2  AAV Vectors 
 AAV is a nonpathogenic, nonautonomous single-stranded DNA parvovirus that 
requires a helper virus such as adenovirus or herpes virus for replication. AAV has 
many serotypes, and among them, AAV2 is well studied and widely used as a gene 
delivery vector. Without the helper virus, the AAV genome remains episomal in 
target cells [ 29 ,  30 ]. Genome integration is observed at a low frequency and at a 
specifi c site on chromosome 19 [ 31 ]. AAV vectors derived from AAV lack viral 
coding sequences and rarely cause toxic and immune reactions, and they are thus 
considered as a promising gene delivery system for clinical use. However, the lim-
ited packaging capacity of AAV (approximately ~5 kb) is a major limitation of this 
vector system [ 32 ]. 
 One interesting property of AAV is that the inverted terminal repeats (ITRs) of 
the AAV genome permit AAV vectors to effi ciently introduce gene-targeting con-
structs into homologous chromosomal loci in a cellular genome [ 33 ]. This unique 
property permits gene editing, and effi cient gene targeting by AAV vectors has been 
achieved in human ES cells and iPS cells [ 34 – 36 ]. Damdindorj et al. [ 37 ] reported 
that when used in an AAV vector, the CMV promoter provided stable and robust 
gene expression in cancer cell lines; however, this promoter does not seem to be 
preferable for noncancerous cell lines and for the purpose of AAV-based gene tar-
geting. Further studies are needed to identify the most suitable constitutive pro-
moter for the application of AAV vectors to precise genetic manipulation of iPS 
cells, which could have great scientifi c and therapeutic potential. 
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11.2.3  Retrovirus Vectors 
 Retroviral vectors are among the most commonly used gene delivery systems for 
target gene transduction. They possess several advantages compared with other 
viral vectors, such as high-level transgene expression activity in long-term culture 
of most dividing somatic cells and their large DNA capacity (9–12 kb) [ 32 ]. 
Retroviral vectors reverse-transcribe their single-stranded RNA genome into DNA 
that is then integrated into target cell genome. According to their genome organiza-
tion, retroviruses are broadly divided into two categories: simple onco-retroviruses, 
such as Moloney murine leukemia virus (MLV), and complex retroviruses including 
lentiviruses, such as human immunodefi ciency virus [ 23 ]. Onco-retrovirus-based 
vectors are not capable of gene transfer to nondividing cells because they rely on 
cell division for transduction. 
 Importantly, transgene expression by MLV-based vectors is restricted in undif-
ferentiated pluripotent stem cells by de novo DNA methylation [ 38 ,  39 ] and other 
mechanisms, such as TRIM28-mediated silencing of the promoter element within 
the MLV long-terminal repeat (LTR) [ 40 ,  41 ]. A retroviral mutant vector, the murine 
ES-cell virus (MESV), was developed to facilitate target gene expression in ES cells 
through its ability to escape immediate silencing and initiate proviral expression 
[ 38 ,  42 ]; however, the MESV vector is still prone to inactivation during long periods 
of culture [ 38 ]. The self-silencing property of retroviral vectors is advantageous 
during reprogramming for iPS cell generation because it is necessary for the forced 
expression of exogenous reprogramming factors to cease once the cell reaches the 
ES-cell-like state. Indeed, Yamanaka and colleagues fi rst generated iPS cells from 
mouse and human fi broblasts using MLA-based vectors [ 2 ,  3 ]. 
 However, the self-silencing property of retroviral transduction in pluripotent 
stem cells would be disadvantageous for molecular studies that require sustained 
expression of exogenous gene products. In addition, retrovirus vectors have the 
potential to induce insertional mutagenesis in iPS cells through their random inte-
gration into the host genome [ 43 ]. These aspects should be carefully considered 
when designing iPS cell experiments using retroviral vector systems. 
11.2.4  Lentivirus Vectors 
 In contrast to onco-retroviruses, lentiviruses are transported to the nucleus of the 
target cells by active transport but do not require cell division for transduction, 
which allows them to transduce quiescent and nondividing cells [ 44 ]. Lentivirus 
vectors have an ~8-kb packaging capacity that limits the introduction of many 
genomic DNA sequences, but most cDNA sequences can be accommodated. Given 
their advantages, lentiviral vectors have become the predominant vectors for gene 
transduction in many types of cells and in transgenic animals [ 45 ]. 
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 Similar to other retroviral vectors, lentiviral vectors possess the ability to inte-
grate into the host genome and stably express the delivered target gene. Although 
insertional mutagenesis by lentiviral vectors is still their major disadvantage, it 
occurs less frequently for lentiviruses than for onco-retroviruses [ 46 ,  47 ]. To reduce 
the risk of insertional mutagenesis, non-integrating lentiviral (NIL) vectors, which 
carry either mutant integrase or mutations in the integrase binding sits, have been 
developed [ 48 – 50 ]. In this vector system, the lentiviral genome remains episomal in 
the nucleus, with sustained transgene expression that does not require genome inte-
gration [ 48 ,  49 ]; therefore, it is expected to provide a safe and promising gene deliv-
ery system for laboratory and clinical use [ 51 ]. 
 One important characteristic of lentivirus vectors is their resistance to silencing 
during propagation and differentiation of ES cells [ 52 ]; as a result, they have become 
widely used for gene transduction in ES cells [ 53 – 56 ]. Hong et al. [ 12 ] demon-
strated that when used in a lentiviral vector, the EF1α promoter drove robust trans-
gene expression in mouse ES cells from undifferentiated status to fully differentiated 
status during neuronal differentiation, whereas the CMV promoter activated trans-
gene expression only in late stages of differentiation. Norrman et al. [ 8 ] reported 
that the use of ACTB, EF1α, and PGK promoters in lentiviral vectors permitted 
stable transgene expression in human ES cells, whereas the CMV promoter was less 
effective and expression was rapidly downregulated within 7 days. 
11.3  Transposon-Based Gene Delivery Systems 
 As a nonviral gene delivery method, electroporation has been widely used for exog-
enous gene expression in ES cells [ 57 ]; however, a major drawback of this method 
is low transfection effi ciency. Transposon DNA vectors have been recently used for 
nonviral gene delivery [ 58 ]. The  piggyBac transposon, a transposon DNA vector 
identifi ed from the cabbage looper moth  Trichoplusia ni [ 59 ], has been reported as 
a highly effi cient tool to insert exogenous genes into mammalian cells [ 60 – 62 ]. The 
 piggyBac transposon system is constituted by two basic elements: a 2,472-bp trans-
poson with 13-bp inverted terminal repeats (ITRs) and a 594 amino acid transposase 
[ 59 ,  63 ]. 
 The  piggyBac transposon mediates gene transfer through a cut-and-paste mecha-
nism (Fig.  11.1 ) [ 58 ], where it is inserted into the genomic DNA at TTAA tetranu-
cleotide sites and then integrates with the chromosomal DNA through the activity of 
the transposase [ 63 ]. This system can effi ciently deliver DNA fragments sized 9 kb, 
even up to 14 kb, without signifi cant decreases in transposition effi ciency [ 60 ]. 
Another advantage is that the  piggyBac transposon can be excised from the original 
insertion site without leaving any remnant sequence [ 64 ]; thus,  piggyBac -mediated 
genetic insertions are reversible. Given its capacity for effi cient and reversible gene 
transfer, the  piggyBac transposon system is a promising vector for gene delivery.
 The  piggyBac transposon system can be used to generate transgene-free iPS cells 
[ 65 – 68 ], which may thus have increased therapeutic utility. Additionally, the 
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 piggyBac transposon system has been used for effi cient gene delivery to human ES 
cells, where the insertion can be removed from the ES genome without leaving any 
insertional mutation as described above [ 69 ,  70 ]. This system has also been used for 
gene delivery to human iPS cells [ 71 – 73 ]. In dental research, a  piggyBac transposon- 
based gene expression system has been applied to human deciduous tooth dental 
pulp cell-derived iPS cells to express EGFP and tdTomato transgenes [ 74 ]. 
11.4  tet-Controlled Transcriptional Regulation System 
 Control of transgene expression is important for preventing potential adverse effects 
of the continued overexpression of the transgene. tet-regulated gene expression sys-
tems are among the most widely used gene regulation systems [ 75 ] and consist of 
two variants: the tet-off and the tet-on systems (Fig.  11.2 ) [ 76 ,  77 ]. In the tet-off 
system, when doxycycline, an analog of tet, is absent, the tet transactivators (tTAs) 
bind to their target element, a tet-operator sequence (tet response element, TRE) 
that is upstream of a promoter, to drive transgene expression. Conversely, in the 
presence of doxycycline, the tTAs cannot bind to the TRE; therefore, transgene 
expression is hindered. The tet-on system was derived from the tet-off system by 
inducing random mutations in the tTAs [ 77 ]. These mutant reverse transactivators 
(rtTAs) bind to the TRE in the presence of doxycycline to drive transgene expres-
sion, and transgene expression does not occur without doxycycline.
 Fig. 11.1  Mechanism of  piggyBac transposition. ( a ) In the transfected cell, transposase is 
expressed from the  piggyBac transposase expression vector, and it then recognizes and binds to the 
specifi c inverted terminal repeats (ITRs) of the transgene vector plasmid and cuts the DNA 
sequence of the transgene from the original sites. Then, the transgene DNA sequence integrates 
into the genomic DNA of the target cell. ( b ) For excision, re-expression of transposase by transfec-
tion of the  piggyBac transposase expression vector leads to cutting of the transgene at the ITRs in 
the genomic DNA, which results in removal of the inserted transgene from the genomic DNA 
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 Controlled regulation of transgene expression has great signifi cance for investi-
gating molecular mechanisms of pluripotency and cellular differentiation in stem 
cells [ 16 ], and tet-controlled transcriptional activation systems have thus been 
applied to pluripotent stem cells [ 17 ,  18 ,  78 ]. Dox-inducible lentiviral and  piggyBac 
vectors have also been used to direct reprogramming of somatic cells to iPS cells 
[ 66 ,  79 ]. This system also permits the regulation of transgene expression in iPS cells 
to drive their differentiation toward specifi c cell lineages such as myocytes 
[ 71 – 73 ]. 
11.5  Conclusions 
 Because each gene delivery system possesses its own characteristics, researchers 
should consider the suitability of the system, rather than technical convenience, for 
a particular iPS cell experiment. The choice of promoter is also important, espe-
cially for experiments in iPS cells. Although little systematic information is avail-
able regarding the activity of constitutive promoters in undifferentiated iPS cells, 
the EF1α and CA promoters, but not the CMV promoter, are expected to be suitable 
for high levels of stable transgene expression. The  piggyBac transposon-based gene 
delivery system provides several benefi ts over classic viral and nonviral gene deliv-
ery systems. In addition, it can be combined with tet-controlled transcriptional regu-
lation to achieve spatiotemporal control of transgene expression during iPS cell 
differentiation, which may provide a great impact on iPS cell research. 
 Fig. 11.2  Tetracycline (tet)-controlled transcriptional regulation systems. ( a ) tet-off system: in the 
presence of doxycycline (Dox), tet transactivators (tTAs) cannot bind to the tet-operator (tetO) 
sequence to induce target gene (transgene) expression. In the absence of Dox, tTAs bind to the tetO 
sequence to drive target gene expression. ( b ) tet-on system: reverse tet transactivators (rtTAs) bind 
to the tetO in the presence of Dox to induce transgene expression. In contrast, in the absence of 
Dox, rtTAs cannot bind to the tetO; thus, transgene expression does not occur 
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